Plasma BNP concentration predicts survival in patients with HF

In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of brain natriuretic peptide (BNP). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma BNP.